Mon Sep 09 15:44:07 UTC 2024: ## Sleep Apnea Patients Seek Pill-Form Treatment, CPAP Machines Fail to Satisfy

**New York, NY – September 9, 2024** – A new survey by Quantum Research Group, LLC reveals widespread dissatisfaction with current sleep apnea treatment methods, with over half of patients reporting dissatisfaction with their current treatment, primarily CPAP machines. The survey, titled “Understanding Obstructive Sleep Apnea Treatment Experiences and Patient Perspectives,” found that a staggering 69% of patients with obstructive sleep apnea (OSA) are eager to switch to a pill-form treatment.

The survey, conducted in May 2024, highlighted the key reasons for patients’ desire for alternative treatment:

* **Ease of use:** 84% of patients willing to switch cited ease of use as the primary driver.
* **Disrupted sleep:** 61% of CPAP users reported frequent sleep disruptions due to the machine.
* **Discomfort:** Nearly 70% of patients found the CPAP machine uncomfortable, with 69% complaining of mask discomfort, 53% experiencing dry mouth or throat, and 47% facing air leaks.
* **Negative impact on quality of life:** 37% of patients reported no improvement or a worsening of their overall quality of life, while 31% experienced similar negative effects on their sleep quality.

The survey underscores the significant need for new treatment options, particularly a pill-form treatment for OSA. This demand is reflected in the burgeoning market for sleep apnea devices, expected to grow from $2.02 billion in 2023 to $3.76 billion by 2032.

Companies like Incannex (NASDAQ: IXHL) are actively developing pill-form treatments for OSA. Incannex’s IHL-42X, a combination of dronabinol and acetazolamide, is currently undergoing Phase 2/3 clinical trials following promising Phase 2 results demonstrating a significant reduction in the Apnea Hypopnea Index (AHI).

“Despite being the standard treatment, studies show that there is low compliance with CPAP machines, and this survey further confirms the need for treatment alternatives,” said Joel Latham, president and CEO of Incannex. “We look forward to advancing our clinical program in the hopes of bringing a medicated treatment option to market, a solution that we believe patients will find more convenient and comfortable.”

The survey findings present a clear call for innovation in the sleep apnea treatment landscape, with patients seeking more comfortable and convenient alternatives to current options. The development of a pill-form treatment holds significant promise for improving the lives of millions suffering from OSA.

Read More